Yuecheng Yang

Yuecheng Yang

Auto-generated profile, based on publicly available information

Yuecheng Yang

Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YYYuecheng Yang
Yuecheng Yang
HLHuanyu Luo
Huanyu Luo
YZYunkui Zhang
Yunkui Zhang
ZZZhiyong Zhao
Zhiyong Zhao
JZJun Zhang
Jun Zhang
Objective: Ketamine, as a sedative, has been administered during mechanical ventilation in critically ill patients; however, its impact on survival outcomes in this patient population remains uncertain. Methods: This retrospective cohort study extracted data from the Medical Information Mart for Intensive Care (MIMIC-IV) database, version 3.0. Patients were categorized into the ketamine group and the control group based on whether ketamine was administered during mechanical ventilation. Propensity score matching was performed to adjust for demographic variables and coexisting conditions. The primary outcome was 28-day mortality. Secondary outcomes included 14-day and 90-day mortality rates, as well as hospital and ICU lengths of stay. Results: The study included a total of 8569 patients, with 330 in the ketamine group and 8239 in the control group. After propensity score matching, significant differences in mechanical ventilation duration and the proportion of patients with acute respiratory distress syndrome remained between groups. No significant differences were observed in 28-day and 90-day mortality rates between the groups. Subgroup analysis indicated that ketamine was associated with lower 14-day mortality rates among younger patients, those with acute respiratory distress syndrome, and norepinephrine users. Ketamine administration was also found to correlate with increased lengths of stay in both the hospital and ICU. Conclusions: Ketamine was more frequently selected for patients requiring prolonged mechanical ventilation. The administration of ketamine was associated with reduced 14-day but not with 28-day or 90-day mortality rates.

1 January 2015 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YYYuecheng Yang
Yuecheng Yang
XHXuehua Huang
Xuehua Huang
YFYinghui Fan
Yinghui Fan
YWYingwei Wang
Yingwei Wang
KMKe Ma
Ke Ma
Objective. The aim of this study was to examine the efficacy and safety of pulsed radiofrequency (PRF) in the treatment of chronic migraine (CM) on cervical 2-3 posterior medial branches.Methods. This randomized, double-blind, and controlled clinical trial included 40 subjects with CM, who were randomly divided into two groups: treatment (treated by PRF) and sham (treated by sham treatment). Pain intensity, headache duration (days), the Migraine Disability Assessment Questionnaire (MIDAS), and aspirin dose taken by patients were evaluated at 1, 2, and 6 months after the intervention. Side effects were observed from the time of treatment and throughout the follow-up period.Results. During the follow-up, pain intensity, headache duration (days), disability score, and the analgesic dose were significantly improved in the treatment group compared to the sham group (P<0.001) and the baseline (P<0.001) at all measured time points after intervention. No serious complications were reported.Conclusion. PRF on the cervical 2-3 posterior medial branches could provide satisfactory efficacy in the treatment of CM without obvious adverse effects.

27 February 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
YYYuecheng Yang
Yuecheng Yang
YZYunkui Zhang
Yunkui Zhang
GZGuoxia Zhou
Guoxia Zhou
ZYZaixian Yang
Zaixian Yang
HYHan Yan
Han Yan
JZJun Zhang
Jun Zhang
Introduction Postoperative sleep disturbances significantly impair postoperative recovery. The administration of intravenous esketamine has been shown to potentially improve postoperative sleep quality. However, the effectiveness of epidural esketamine in improving postoperative sleep quality remains to be elucidated. This study aims to explore the impact of both intraoperative and postoperative use of epidural esketamine on the postoperative sleep quality of patients undergoing minimally invasive lower abdominal surgeries. Methods and analysis This randomised, double-blind, parallel-group, placebo-controlled trial will be conducted at the Fudan University Shanghai Cancer Centre. A total of 128 adults undergoing minimally invasive lower abdominal surgeries will be randomly allocated in a 1:1 ratio to either the esketamine group or the placebo group. In the esketamine group, epidural esketamine will be administered intraoperatively (0.2 mg/kg) and postoperatively (25 mg). Postoperatively, all patients will receive epidural analgesia. The primary outcome of the study is the incidence of poor sleep quality on the third day after surgery. The sleep quality assessment will be conducted using the Pittsburgh Sleep Quality Index and a Numeric Rating Scale of sleep. The main secondary outcomes include postoperative pain and anxiety and depression scores. The postoperative pain, both rest pain and movement pain, will be assessed using a Numerical Rating Scale within 5 days after surgery. Anxiety and depression scores will be evaluated using the Hospital Anxiety and Depression Scale both before and after the surgery. Safety outcomes will include delirium, fidgeting, hallucinations, dizziness and nightmares. The analyses will be performed in accordance with intention-to-treat principle Ethics and dissemination Ethics approval has been obtained from the Ethics Committee of the Shanghai Cancer Centre (2309281-9). Prior to participation, all patients will provide written informed consent. The results of the trial are intended to be published in a peer-reviewed journal. Trial registration number ChiCTR2300076862.

21 December 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YYYuecheng Yang
Yuecheng Yang
YZYunkui Zhang
Yunkui Zhang
YTYonghong Tang
Yonghong Tang
JZJun Zhang
Jun Zhang
Objective: Anesthesia is correlated with the prognosis of cancer surgery. However, evidence from prospective studies focusing on breast cancer is currently limited. This systematic review aimed to investigate the effect of anesthesia-related interventions on oncological outcomes following breast cancer surgery in prospective studies. Methods: Literature searches were performed from inception to June. 2023 in the Pubmed, Web of Science, Embase, and ClinicalTrials databases. The main inclusion criteria comprised a minimum of one-year follow-up duration, with oncological outcomes as endpoints. Anesthesia-related interventions encompassed, but were not limited to, type of anesthesia, anesthetics, and analgesics. The risk of bias was assessed using the Cochrane Risk of Bias Tool. Results: A total of 9 studies were included. Anesthesia-related interventions included paravertebral nerve block (3), pectoral nerve block (1), sevoflurane (2), ketorolac (2), and infiltration of lidocaine (1). Cancer recurrence, metastasis, disease-free survival, or (and) overall survival were assessed. Among all included studies, only infiltration of lidocaine was found to prolong disease-free survival and overall survival. Conclusion: Regional anesthesia and propofol did not improve oncological outcomes following breast cancer surgery. The anti-tumorigenic effect of ketorolac warrants future studies with larger sample sizes. Perioperative infiltration of lidocaine around the tumor may be a promising anti-tumorigenic intervention that can prolong overall survival in patients with early breast cancer.

5 July 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
YYYuecheng Yang
Yuecheng Yang
JZJingying Zhang
Jingying Zhang
HWHaoyuan Wang
Haoyuan Wang
YZYunkui Zhang
Yunkui Zhang
JZJun Zhang
Jun Zhang
Objective This study investigates the effects of dexmedetomidine on short-term and long-term survival rates in intensive care unit (ICU) patients with ischaemic stroke. Design This is a retrospective study. Setting Data were sourced from the Medical Information Mart for Intensive Care IV database. Participants This study analysed 2816 patients with ischaemic stroke from the US Intensive Care database. Interventions Dexmedetomidine administration during the ICU stay was defined as the exposure. Methods Patients were categorised into the dexmedetomidine group and the control group. Cox regression analysis was used to identify factors that may influence the 28-day mortality rate of patients with ischaemic stroke. High-risk factors were incorporated as covariates, and a 1:1 propensity score matching using the logit model was constructed to compare the prognosis between the two groups. Primary and secondary outcome measures The primary outcome was 28-day mortality. The secondary outcomes included in-hospital mortality, ICU length of stay, hospital length of stay, mechanical ventilation duration and 180-day mortality in discharged patients. Results A total of 2816 patients were included. Cox regression analysis revealed that dexmedetomidine use was associated with a reduced risk of 28-day mortality. Following propensity score matching, each group comprised 407 patients. Dexmedetomidine was found to improve 28-day mortality (27.8% vs 36.6%, p=0.007). However, it was also associated with the prolonged length of hospital and ICU stay (p=0.002). Among discharged patients, dexmedetomidine use was also associated with an improved 180-day mortality rate (p=0.0019). Conclusion The use of dexmedetomidine is associated with improved short-term and long-term prognosis in patients with ischaemic stroke and could potentially confer benefits in those receiving mechanical ventilation.

1 August 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
HLHuanyu Luo
Huanyu Luo
YYYuecheng Yang
Yuecheng Yang
ZHZhiyong He
Zhiyong He
CPCongxia Pan
Congxia Pan
XWXing Wu
Xing Wu
JZJun Zhang
Jun Zhang
Objective: This study aims to evaluate the efficacy of esketamine as an epidural adjuvant in mitigating postoperative pain, particularly following the discontinuation of epidural analgesia in patients undergoing open surgery for gynecological malignancies. Design: A randomized controlled trial. Methods: Eighty-eight patients were randomized to receive either esketamine (0.4 mg/kg) combined with sufentanil and ropivacaine (eskatamine group) or sufentanil and ropivacaine alone (control group) via patient-controlled epidural analgesia. Primary outcomes included pain scores on postoperative day 3, assessed using the numeric rating scale. Secondary outcomes included pain scores on postoperative days 1 to 4, Quality of Recovery-15 scores, rescue analgesic requirements, and adverse events. Results: The eskatamine group demonstrated a significant reduction in nocturnal pain intensity on postoperative day 2 compared with controls (median 3.0 vs 4.0, P = 0.044), with fewer patients requiring rescue analgesics on postoperative day 3 (13.4% vs 32.6%, P = 0.036). However, no significant differences were observed in rest pain, movement pain, or breakthrough pain across postoperative day 1– 4. Subgroup analysis revealed higher Recovery-15 scores for moderate pain in the esketamine group (median 10 vs 9, P = 0.048). Transient dizziness was more frequent in the esketamine group (47.7% vs 23.3%, P = 0.017), but no persistent adverse effects were observed. Conclusion: Esketamine, as an adjuvant in patient-controlled epidural analgesia, reduced nocturnal pain on postoperative day 2, shorten the moderate pain duration and lower rescue analgesics within 24 hours after the removal of analgesia device. However, it did not affect pain scores although less rescue analgesia was needed on postoperative day 3.